Automated platform could slash the cost of CAR-T manufacturing, ThermoGenesis – BioPharma-Reporter.com
BioPharma-Reporter.com |
Automated platform could slash the cost of CAR–T manufacturing, ThermoGenesis
BioPharma-Reporter.com In August, Novartis made history when its product Kymriah (tisagenlecleucel) became the first chimeric antigen receptor (CAR) T-cell therapy to win US approval. The product is made by collecting a patient's cells through apheresis at a specialised … |
